Divergent gene expression of PTGS1 and PTGS2 along the disease course of chronic myeloid leukaemia
These findings suggest a potential role of inflammatory pathways in CML progression and treatment response. The upregulation of <i>PTGS1</i> and <i>PTGS2</i> in patients with controlled disease and after imatinib treatment may indicate a link between COX enzyme activity and leukemogenesis. Further investigation is warranted to clarify the mechanistic role of these genes in CML pathophysiology and therapy outcomes.
Authors
- Bianca Kusma
- Anelis Maria Marin (ORCID: https://orcid.org/0000-0003-2260-7949)
- Eulália Mendes (ORCID: https://orcid.org/0000-0002-9155-6367)
- Mateus Nóbrega Aoki (ORCID: https://orcid.org/0000-0001-5166-2897)
- João Samuel de Holanda Farias (ORCID: https://orcid.org/0000-0002-8625-919X)
- Dalila Lucíola Zanette (ORCID: https://orcid.org/0000-0001-9397-4127)
- Denise Kusma Wosniaki (ORCID: https://orcid.org/0000-0002-8248-0831)
- Eduardo Munhoz
Institutions
- Hospital Erasto Gaertner (BR)
- Fundação Carlos Chagas (BR)
- Fundação Oswaldo Cruz (BR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.3389/fonc.2025.1556956
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Araucária